Commenters on the FDA's guidance on clinical investigations and drug development programs for psychedelic drugs raised concerns about decoupling drug administration from psychotherapy support, the proposed credentials for lead safety monitors and the agency’s characterization of the abuse potential of psychedelic drugs....
UW–Madison has joined a statewide consortium, mobilizing its experience and expertise as a collaborative powerhouse in bioscience and technology to help bolster Wisconsin’s leadership in personalized medicine and biohealth technology....
Arabs are are often categorized as white in clinical research. Grouping individuals from diverse genetic backgrounds under a single racial category can be problematic in clinical research....
Since 1973, UW Carbone has remained at the forefront of life-saving discoveries as Wisconsin’s only National Cancer Institute (NCI)-designated comprehensive cancer center....
The University of Wisconsin–Madison has performed well in several recent rankings, including being named one of America’s Best Colleges by Money Magazine....
Working with scientists at the pharmaceutical maker Merck & Co. Inc., UW–Madison chemists and engineers sought to develop a more sustainable method to manufacture ingredients needed to make many types of drugs....
n a recent Clinical Leader Live! episode hosted by Life Science Leader Chief Editor Ben Comer, clinical trial experts Mitchell Katz, SVP, global clinical operations at Kyowa Kirin; Jessica Powell, VP, clinical operations at Alto Neuroscience; and Michael Krams, chief quantitative medicine officer at Exscientia,...
Sponsors can employ several postmarketing strategies to beef up safety and efficacy data on populations that were under-represented in initial clinical trials of drugs and biologics, according to new draft guidance issued by the US Food and Drug Administration (FDA)....
With the rise of generative AI models like ChatGPT, there come questions of how this technology can be used in industry, especially in healthcare....
Principal investigators recognize the need for greater diversity among participants in the clinical trials they run but are frustrated that the inclusion/exclusion criteria handed to them by sponsors often don't match the real-life situations of the average patient in their practice with the condition of...
